PURPOSE: To explore the association between baseline quality of life (QOL) scores and overall survival (OS) in ovarian cancer patients receiving adjuvant chemotherapy. METHODS:Patients with stage III ovarian cancer on Gynecologic Oncology Group protocol #172 completed theFunctional Assessment of Cancer Therapy-General (FACT-G) and were then randomly assigned to either intravenous (IV) or intraperitoneal (IP) chemotherapy. The FACT scale includes physical, functional, social, and emotional well-being domains (PWB, FWB, SWB, EWB). The PWB item, lack of energy, was used to assess the presence of fatigue. RESULTS: After adjusting for patient age, treatment assignment, and the presence of gross disease, PWB was associated with OS. Patients who reported baseline PWB scores in the lowest 25% (PWB score<15 points) relative to those who scored in the highest 25% (PWB score>24 points) had decreased OS (HR: 1.81; 95% CI: 1.2-2.72; p=0.005). Patients experienced death rates 20% lower for every mean item point increase in PWB (Hazard Ratio [HR]: 0.80; 95% CI: 0.68-0.93; p=0.005). Patients complaining of fatigue did not have an increased risk of death compared with those not feeling fatigued (HR: 1.21; 95% CI: 0.91-1.61; p=0.19). CONCLUSIONS: Poor physical well-being reported at baseline is associated with risk of death in patients undergoing adjuvant chemotherapy for advanced ovarian cancer. Identifying modifiable characteristics that are associated with survival offers the potential for providing support that may improve outcomes.
RCT Entities:
PURPOSE: To explore the association between baseline quality of life (QOL) scores and overall survival (OS) in ovarian cancerpatients receiving adjuvant chemotherapy. METHODS:Patients with stage III ovarian cancer on Gynecologic Oncology Group protocol #172 completed the Functional Assessment of Cancer Therapy-General (FACT-G) and were then randomly assigned to either intravenous (IV) or intraperitoneal (IP) chemotherapy. The FACT scale includes physical, functional, social, and emotional well-being domains (PWB, FWB, SWB, EWB). The PWB item, lack of energy, was used to assess the presence of fatigue. RESULTS: After adjusting for patient age, treatment assignment, and the presence of gross disease, PWB was associated with OS. Patients who reported baseline PWB scores in the lowest 25% (PWB score<15 points) relative to those who scored in the highest 25% (PWB score>24 points) had decreased OS (HR: 1.81; 95% CI: 1.2-2.72; p=0.005). Patients experienced death rates 20% lower for every mean item point increase in PWB (Hazard Ratio [HR]: 0.80; 95% CI: 0.68-0.93; p=0.005). Patients complaining of fatigue did not have an increased risk of death compared with those not feeling fatigued (HR: 1.21; 95% CI: 0.91-1.61; p=0.19). CONCLUSIONS: Poor physical well-being reported at baseline is associated with risk of death in patients undergoing adjuvant chemotherapy for advanced ovarian cancer. Identifying modifiable characteristics that are associated with survival offers the potential for providing support that may improve outcomes.
Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel Journal: J Pain Symptom Manage Date: 2010-05 Impact factor: 3.612
Authors: Marilyn L Kwan; Isaac Joshua Ergas; Carol P Somkin; Charles P Quesenberry; Alfred I Neugut; Dawn L Hershman; Jeanne Mandelblatt; Michael P Pelayo; Allegra W Timperi; Sunita Q Miles; Lawrence H Kushi Journal: Breast Cancer Res Treat Date: 2010-02-06 Impact factor: 4.872
Authors: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel Journal: Cancer Date: 2009-10-15 Impact factor: 6.860
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Vivian E von Gruenigen; Heidi E Frasure; Eric L Jenison; Michael P Hopkins; Karen M Gil Journal: Gynecol Oncol Date: 2006-03-23 Impact factor: 5.482
Authors: Vivian E von Gruenigen; Helen Q Huang; Jan H Beumer; Heather A Lankes; William Tew; Thomas Herzog; Arti Hurria; Robert S Mannel; Tina Rizack; Lisa M Landrum; Peter G Rose; Ritu Salani; William H Bradley; Thomas J Rutherford; Robert V Higgins; Angeles Alvarez Secord; Gini Fleming Journal: Gynecol Oncol Date: 2017-01-13 Impact factor: 5.482
Authors: Kemi M Doll; Alison K Kalinowski; Anna C Snavely; Debra E Irwin; Jeannette T Bensen; Victoria L Bae-Jump; Kenneth H Kim; Linda Van Le; Daniel L Clarke-Pearson; Paola A Gehrig Journal: Cancer Date: 2014-09-23 Impact factor: 6.860
Authors: N T Phippen; A A Secord; S Wolf; G Samsa; B Davidson; A P Abernethy; D Cella; L J Havrilesky; R A Burger; B J Monk; C A Leath Journal: Gynecol Oncol Date: 2017-07-23 Impact factor: 5.482
Authors: Alaina J Brown; Charlotte C Sun; Diana Urbauer; Donna S Zhukovsky; Charles Levenback; Michael Frumovitz; Premal H Thaker; Diane C Bodurka; Lois M Ramondetta Journal: Support Care Cancer Date: 2014-12-18 Impact factor: 3.603
Authors: Bradley J Monk; Helen Q Huang; Robert A Burger; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Sharon X Liang; Lari Wenzel Journal: Gynecol Oncol Date: 2012-12-04 Impact factor: 5.482
Authors: K M Doll; A C Snavely; A Kalinowski; D E Irwin; J T Bensen; V Bae-Jump; J F Boggess; J T Soper; W R Brewster; P A Gehrig Journal: Gynecol Oncol Date: 2014-04-12 Impact factor: 5.482